Autologous Conditioned Serum

Christopher H. Evans, Xavier Chevalier, Peter Wehling

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine interleukin-1. The latter is thought to be an important mediator of inflammation, pain, and tissue destruction in musculoskeletal conditions. ACS has been widely and successfully used in the local treatment of human and equine osteoarthritis and radicular compression; it has also shown promise in treating tendinopathies, muscle injuries, and tunnel widening after reconstruction of the anterior cruciate ligament. Experience suggests that autologous conditioned serum is safe and effective.

Original languageEnglish (US)
Pages (from-to)893-908
Number of pages16
JournalPhysical Medicine and Rehabilitation Clinics of North America
Issue number4
StatePublished - Nov 1 2016


  • Anterior cruciate ligament
  • Interleukin-1 receptor antagonist
  • Intra-articular therapy
  • Muscle injury
  • Osteoarthritis
  • Pain
  • Radicular compression
  • Tendinopathy

ASJC Scopus subject areas

  • Physical Therapy, Sports Therapy and Rehabilitation
  • Rehabilitation


Dive into the research topics of 'Autologous Conditioned Serum'. Together they form a unique fingerprint.

Cite this